21585-16-0

Usage

Uses

Used in Pharmaceutical Industry:
2,3-dihydro-5-(2-hydroxyethyl)-6-methyl-2-thioxo-1H-pyrimidin-4-one is used as a xanthine oxidase inhibitor for the treatment of gout and kidney stones. It helps decrease uric acid production, preventing crystal formation and alleviating associated pain and inflammation.
Common side effects of Allopurinol may include skin rash, diarrhea, and drowsiness. It is crucial for patients to undergo regular monitoring by a healthcare provider during the course of treatment to ensure safety and effectiveness.

InChI:InChI=1/C7H10N2O2S/c1-4-5(2-3-10)6(11)9-7(12)8-4/h10H,2-3H2,1H3,(H2,8,9,11,12)

Upstream product

• 517-23-7 3-acetyl-2-oxo-4,5-dihydrofuran 
• 17356-08-0 thiourea 
• 86351-01-1 2-(2-hydroxy-ethyl)-acetoacetic acid ethyl ester 

Downstream Products

• 98489-83-9 5-(2-hydroxyethyl)-6-methyl-2-methylthiopyrimidin-4(3H)-one 
• 23935-66-2 5-(2-hydroxyethyl)-6-methyluracil 
• 78831-58-0 2-(4-Methyl-5,6-dihydro-furo[2,3-d]pyrimidin-2-yl)-isothiourea; hydrobromide 
• 78831-51-3 2-<5-(1,2,3,4-tetrahydro-6-methyl-2,4-dioxopyrimidinyl)>ethylthiouronium bromide 
• 78831-52-4 2-<5-(1,2,3,4-tetrahydro-6-methyl-2,4-dioxopyrimidinyl)>ethanethiol 
• 178268-48-9 7-(4-Fluoro-phenyl)-4-methyl-2-methylsulfanyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 
• 74187-94-3 2-Hydrazino-5-(2-hydroxy-ethyl)-6-methyl-3H-pyrimidin-4-one 
• 86487-53-8 2,3-dihydro-6-(2-hydroxyethyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one 

Relevant academic research and scientific papers

Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites

The present invention relates to a group of novel tetrahydropyridin-4-yl indoles with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine-D2 receptors, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said tetrahydropyridin-4-yl indoles. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The invention relates to novel tetrahydropyridin-4-yl indoles of the formula. and tautomers, stereoisomers, prodrugs, N-oxides, pharmacologically acceptable salts, hydrates and solvates thereof, wherein: R1 is hydrogen, halogen, alkyl(C1-3) or alkoxy(C1-3), CN or CF3, R2 is hydrogen or alkyl(C1-3), R3 is hydrogen or alkyl(C1-3), Z is hydrogen or alkyl(C1-3), alkoxy(C1-3) or alkylthio(C1-3), A is hydrogen or alkyl(C1-3), or A and Z together form a saturated or (partly) unsaturated 5- or 6-membered ring which may be substituted with halogen, alkyl (C1-3) or phenyl, in which ring Z represents carbon, sulfur of nitrogen.

4-(1H-INDOL-1-YL)-1-PIPERIDINYL DERIVATIVES

The present invention concerns the compounds of formula STR1 the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein the dashed line designates an optional bond; R 1 and R 2 are each independently hydrogen, halogen, C. sub.1-6 alkyl or C. sub.1-6 alkyloxy; R 3 and R. sup.4 are each independently hydrogen, C 1-6 alkyl, phenyl or phenyl substituted with one, two or three substituents selected from halo, hydroxy, nitro, cyano, trifluoromethyl, C 1-6 alkyl, C 1-6 alkyloxy, C 1-6 alkylthio, mercapto, amino, mono-and di(C 1-6 alkyl)-amino, carboxyl, C 1-6 alkyloxycarbonyl and C 1-6 alkylcarbonyl; Alk is C 1-4 alkanediyl; D is a pyrimidinone, piperidone or a benzimidozolidinone; having antipsychotic activity; their preparation, compositions containing them and their use as a medicine.

Synthesis and in vitro evaluation of some new pyrimidines and related condensed ring systems as potential anticancer agents

Several new pyrimidines 6-11, 18-20, furo-, thieno-, and pyrrolo[2,3-d]pyrimidines 3, 8, 12, triazolo[4,3-a]pyrimidines 14, 15, 16 and tetrazolo[1,5-a]pyrimidine 17 were prepared from the known intermediate 5-(2-hydroxyethyl)-6-methyl-2-thiouracil (2). Compound 7 (4-chloro-5-(2-chloroethyl)-2-methylthio-6-methyl-pyrimidine) exhibited weak antitumor activity in vitro.